ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
As solar construction in China cools, Hainan Drinda looks for relief overseas
002865.SHE
